Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for ...

Years of layoffs and alleged mismanagement have left employees “sick” of the pharmaceutical contract manufacturer Catalent, ...

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...

Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not ...

The European Commission granted unconditional approval to Novo Holdings’ $16.5 billion takeover of Catalent, a decision both ...

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Catalent (CTLT) shares rise 1% as Novo Holdings explores contract extensions with concerned drugmakers post $16.5 billion ...

Catalent, Inc. ("Catalent," NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences ...